Francesco Londero1#, Gianluca Masullo1#, William Grossi1, Elisa De Franceschi1, Jacqueline Cinel1, Nicola Vernaccini2, Nunzio Davide de Manna1, Stefano Bacchetti2, Igor Vendramin1, Gianluigi Adani2, Angelo Morelli1 and Enrico Maria Pasqual2*
1Department of Cardiothoracic Surgery, Azienda Sanitaria Universitaria Friuli Centrale, University Hospital Santa Maria della Misericordia, Italy
2Department of General Surgery, Center for Advanced Surgical Oncology, Azienda Sanitaria Universitaria Friuli Centrale, University Hospital Santa Maria della Misericordia, Italy
#These authors contributed equally to this work
Background: Pleural malignancies are challenging conditions in terms of possibility of cure. Recent growing interest towards Hyperthermic Intrathoracic Chemotherapy (HITHOC) after Cytoreductive Surgery (CRS) has been referred. Minimally invasive approach (VATS) may be suggest in this context but evidence is still lacking. Methods: A preliminary experience in seven patients submitted to cytoreductive surgery and HITHOC is described, with a focus on technical aspects related to VATS approach, operating median time and postoperative complication. Results: A triportal VATS approach has been employed in all cases. Median time of surgery including pleural perfusion was 200 min (range 165 to 370). Mean blood loss was 217 cc (range 100 and 600). Thirty days mortality was nothing. Conclusion: VATS cytoreductive surgery and HITHOC is a safe procedure and could be proposed in the setting of a multimodality strategy employing adjuvant radio-chemotherapy in referral centers.
Pleura; Mesothelioma; Thymoma; HITHOC; Cytoreductive surgery; VATS
Londero F, Masullo G, Grossi W, De Franceschi E, Cinel J, Vernaccini N, et al. Cytoreductive Surgery and Hyperthermic Intrathoracic Chemotherapy by Video-Assisted Surgery for Pleural Malignancies: Technical Aspects and Safety Profile. Clin Surg. 2021; 6: 3339.